Pfizer ordered to withdraw journal ad

A UK government agency told Pfizer to take down an ad for Zyvox due to potentially misleading claims about the antibiotic. The ads had run in the British Medical Journal and claimed that Zyvox (linezolid) has “superior cure rates” compared to products containing the active ingredient vancomycin, according to the UK-based Medicines and Healthcare products Regulatory Agency (MHRA). Pfizer suspended all advertising containing the claim, MHRA said, although the agency advised the firm to continually review its advertising to ensure the right balance of risks and benefits is presented and to take appropriate action if new safety data becomes available. Pfizer wrote to healthcare professionals this week to inform them about new safety restrictions on the use of Zyvox.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.